- Home
- IREN vs ARQT Comparison
IREN vs ARQT Comparison
Compare IREN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- ARQT
- Stock Information
- Founded
- IREN 2018
- ARQT 2016
- Country
- IREN Australia
- ARQT United States
- Employees
- IREN N/A
- ARQT N/A
- Industry
- IREN EDP Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- IREN Technology
- ARQT Health Care
- Exchange
- IREN Nasdaq
- ARQT Nasdaq
- Market Cap
- IREN 2.5B
- ARQT 1.7B
- IPO Year
- IREN 2021
- ARQT 2020
- Fundamental
- Price
- IREN $16.81
- ARQT $14.24
- Analyst Decision
- IREN Strong Buy
- ARQT Strong Buy
- Analyst Count
- IREN 11
- ARQT 6
- Target Price
- IREN $19.20
- ARQT $18.80
- AVG Volume (30 Days)
- IREN 27.7M
- ARQT 2.0M
- Earning Date
- IREN 08-27-2025
- ARQT 08-13-2025
- Dividend Yield
- IREN N/A
- ARQT N/A
- EPS Growth
- IREN N/A
- ARQT N/A
- EPS
- IREN N/A
- ARQT N/A
- Revenue
- IREN $377,821,000.00
- ARQT $212,819,000.00
- Revenue This Year
- IREN $167.49
- ARQT $61.15
- Revenue Next Year
- IREN $79.42
- ARQT $37.98
- P/E Ratio
- IREN N/A
- ARQT N/A
- Revenue Growth
- IREN 128.24
- ARQT 100.03
- 52 Week Low
- IREN $5.13
- ARQT $7.86
- 52 Week High
- IREN $18.54
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- IREN 87.92
- ARQT 52.81
- Support Level
- IREN $15.18
- ARQT $13.06
- Resistance Level
- IREN $18.30
- ARQT $14.31
- Average True Range (ATR)
- IREN 1.30
- ARQT 0.60
- MACD
- IREN 0.46
- ARQT -0.00
- Stochastic Oscillator
- IREN 85.91
- ARQT 61.96
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.